Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression.

Published on Feb 21, 2020in International Journal of Molecular Sciences4.556
· DOI :10.3390/IJMS21041475
Vera Cappelletti21
Estimated H-index: 21
Elena Verzoni17
Estimated H-index: 17
+ 9 AuthorsGiuseppe Procopio31
Estimated H-index: 31
Circulating tumor cells (CTCs) are promising biomarkers for prognosis, therapeutic response prediction, and treatment monitoring in cancer patients. Despite its epithelial origin, renal cell carcinoma (RCC) shows low expression of epithelial markers hindering CTC-enrichment approaches exploiting epithelial cell surface proteins. In 21 blood samples serially collected from 10 patients with metastatic RCC entering the TARIBO trial, we overcame this limitation using the marker-independent Parsortix™ approach for CTC-enrichment coupled with positive and negative selection with the DEPArray™ with single cell recovery and analysis for copy number alterations (CNA) by next generation sequencing NGS. Two CTC subpopulations were identified: epithelial CTC (eCTC) and non-conventional CTC (ncCTC) lacking epithelial and leukocyte markers. With a threshold ≥1CTC/10 mL of blood, the positivity rates were 28% for eCTC, 62% for ncCTCs, and 71% considering both CTC types. In two patients with detectable eCTCs at baseline, progression free survival was less than 5 months. In an index case, hierarchical structure by translational oncology (TRONCO) identified three clones among 14 CTCs collected at progression and at baseline, each containing cells with a 9p21.3loss, a well-known metastasis driving subclonal alteration. CTCs detection in RCC can be increased by marker-independent approaches, and CTC molecular characterization can allow detection of subclonal events possibly related to tumor progression.
📖 Papers frequently viewed together
28 Citations
59 Citations
1 Citations
In biliary tract cancer (BTC), tissue biopsies to guide treatment are rarely feasible, thus implementing liquid biopsy approaches to improve patient management represents a priority. So far, studies on circulating tumor cells (CTCs) in BTC are insufficient to promote their use in patient clinical management and are limited to EpCAM-enriched CTCs evaluated with the CellSearch. We applied a single-cell protocol allowing identification not only of epithelial CTCs (eCTCs), but also of nonconventiona...
2 CitationsSource
#1Aparna Raj Parikh (Harvard University)H-Index: 13
#2Ignaty Leshchiner (Broad Institute)H-Index: 28
Last. Ryan B. Corcoran (Harvard University)H-Index: 39
view all 47 authors...
During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor subclones harboring unique resistance mechanisms in an individual patient1–3. Previous case reports and small case series have suggested that liquid biopsy (specifically, cell-free DNA (cfDNA)) may better capture the heterogeneity of acquired resistance4–8. However, the effectiveness of cfDNA versus standard single-lesion tumor biopsies has not been directly compared in larger-scale prospective cohorts of patien...
93 CitationsSource
Single-cell technologies have contributed to unravelling tumour heterogeneity, now considered a hallmark of cancer and one of the main causes of tumour resistance to cancer therapies. Liquid biopsy (LB), defined as the detection and analysis of cells or cell products released by tumours into the blood, offers an appealing minimally invasive approach that allows the characterization and monitoring of tumour heterogeneity in individual patients. Here, we will review and discuss how circulating tum...
86 CitationsSource
#1Zhenlong YeH-Index: 1
#2Yong-Mei Ding ('SMMU': Second Military Medical University)H-Index: 3
Last. Qian Qijun ('SMMU': Second Military Medical University)H-Index: 2
view all 12 authors...
ABSTRACTCirculating tumor cells (CTCs) have been exclusively studied and served to assess the clinical outcomes of treatments and progression of cancer. Most CTC data have mainly been derived from distinct cohorts or selected tumor types. In the present study, a total of 594 blood samples from 479 cases with 19 different carcinomas and 30 healthy samples were collected and analyzed by Subtraction enrichment method combined with immunostaining-fluorescence in situ hybridization (iFISH). Non-hemat...
9 CitationsSource
#1Matteo SantoniH-Index: 36
#2Alessia Cimadamore (United Hospitals)H-Index: 13
Last. Rodolfo MontironiH-Index: 12
view all 10 authors...
9 CitationsSource
#1M. Craig MillerH-Index: 34
#2Peggy S. RobinsonH-Index: 1
Last. Daniel J. O'ShannessyH-Index: 1
view all 4 authors...
: Cancer cells from solid tumors can enter the circulatory system and survive to subsequently form distant metastases. The CellSearch® system (Menarini-Silicon Biosystems, Huntingdon Valley, PA) was the first, FDA-cleared system that provided a reliable tool for the investigation of circulating tumor cells (CTCs), which have been shown to be strongly associated with poor survival and therapy failure. Since that time, a number of new technologies have been introduced to improve CTC detection and/...
27 CitationsSource
#1Mariano Di TrapaniH-Index: 1
#2Nicolò ManaresiH-Index: 21
Last. Gianni MedoroH-Index: 15
view all 3 authors...
: Circulating tumor cells (CTCs) are rare cells shed into the bloodstream by invasive tumors and their analysis offers a promising noninvasive tool to predict and monitor therapeutic responses. CTCs can be isolated from patient blood and their characterization at single-cell level can inform on the genomic landscape of a tumor. All CTC enrichment methods bear a burden of contaminating normal cells, which mandate a further step of purification to enable reliable downstream genetic analysis. Here,...
16 CitationsSource
#1Lucile Broncy (Paris V: Paris Descartes University)H-Index: 5
#2Patrizia Paterlini-Bréchot (Paris V: Paris Descartes University)H-Index: 32
Renal cell carcinoma is a highly malignant cancer that would benefit from non-invasive innovative markers providing early diagnosis and recurrence detection. Circulating tumor cells are a particularly promising marker of tumor invasion that could be used to improve the management of patients with RCC. However, the extensive genetic and immunophenotypic heterogeneity of cells from RCC and their trend to transition to the mesenchymal phenotype when they circulate in blood constitute a challenge fo...
5 CitationsSource
#1Arnaud Méjean (Paris V: Paris Descartes University)H-Index: 49
#2A. Ravaud (Paris V: Paris Descartes University)H-Index: 4
Last. Bernard Escudier (Paris V: Paris Descartes University)H-Index: 1
view all 29 authors...
Abstract Background Cytoreductive nephrectomy has been the standard of care in metastatic renal-cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies. However, the efficacy of targeted therapies has challenged this standard. We assessed the role of nephrectomy in patients with metastatic renal-cell carcinoma who were receiving targeted therapies. Methods In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with confirmed metastatic clear-ce...
271 CitationsSource
#1Elena VerzoniH-Index: 17
#2Raffaele RattaH-Index: 10
Last. Giuseppe ProcopioH-Index: 31
view all 11 authors...
Purpose:Two randomized trials in the cytokine era showed that cytoreductive nephrectomy (CN) had a role in metastatic renal cell carcinoma (mRCC), increasing life expectancy. The survival benefit of tyrosine kinase inhibitors (TKIs), including first-line sunitinib and pazopanib, in mRCC has been demonstrated, but the majority of patients enrolled in the pivotal phase III studies had undergone nephrectomy. Therefore it is unknown if similar survival benefit with targeted agents could be achieved ...
9 CitationsSource
Cited By4
#1Yuri Belotti (NUS: National University of Singapore)H-Index: 2
#2Chwee Teck Lim (NUS: National University of Singapore)H-Index: 88
#1Shen Wang (Lehigh University)
#2Yuyuan Zhou (Lehigh University)
Last. Yaling Liu (Lehigh University)H-Index: 39
view all 6 authors...
Detection and characterization of rare circulating tumor cells (CTCs) in patients' blood is important for the diagnosis and monitoring of cancer. The traditional way of counting CTCs via fluorescent images requires a series of tedious experimental procedures and often impacts the viability of cells. Here we present a method for label-free detection of CTCs from patient blood samples, by taking advantage of data analysis of bright field microscopy images. The approach uses the convolutional neura...
#1Alessia Cimadamore (United Hospitals)H-Index: 13
#2Gaetano Aurilio (IEO: European Institute of Oncology)H-Index: 13
Last. Rodolfo Montironi (United Hospitals)H-Index: 73
view all 9 authors...
Current developments in the treatment of genitourinary tumors underline the unmet clinical need for biomarkers to improve decision-making in a challenging clinical setting. The detection of circulating tumor cells (CTCs) has become one of the most exciting and important new approaches to identifying biomarkers at different stages of disease in a non-invasive way. Potential applications of CTCs include monitoring treatment efficacy and early detection of progression, selecting tailored therapies,...
1 CitationsSource